Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Saved in:
| Title: | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. |
|---|---|
| Authors: | Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. jeffrey.weber@nyulangone.org., Poretta T; Bristol Myers Squibb, Princeton, NJ, USA., Stwalley BD; Bristol Myers Squibb, Princeton, NJ, USA., Sakkal LA; Bristol Myers Squibb, Princeton, NJ, USA., Du EX; Analysis Group, Inc., Los Angeles, CA, USA., Wang T; Analysis Group, Inc., Los Angeles, CA, USA., Chen Y; Analysis Group, Inc., Los Angeles, CA, USA., Wang Y; Analysis Group, Inc., Los Angeles, CA, USA., Betts KA; Analysis Group, Inc., Los Angeles, CA, USA., Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Apr; Vol. 72 (4), pp. 955. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
